TERM ID="NYU_TERM_1" STRING="BRAF inhibition" FREQUENCY=1 START=1301 END=1316 LEMMA="BRAF INHIBITION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_2" STRING="BRAF inhibitors" FREQUENCY=1 START=193 END=208 LEMMA="BRAF INHIBITOR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_3" STRING="BRAFi" FREQUENCY=1 START=210 END=215 LEMMA="BRAF INHIBITORS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_4" STRING="CA209-037 study" FREQUENCY=1 START=642 END=657 LEMMA="CA209-037 STUDY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_5" STRING="ESMO" FREQUENCY=3 START=559 END=563 LEMMA="ESMO" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_6" STRING="ESMO" FREQUENCY=3 START=1240 END=1244 LEMMA="ESMO" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_7" STRING="ESMO" FREQUENCY=3 START=1401 END=1405 LEMMA="ESMO" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_8" STRING="Further advances" FREQUENCY=1 START=429 END=445 LEMMA="FURTHER ADVANCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_9" STRING="Immunotherapies" FREQUENCY=1 START=0 END=15 LEMMA="IMMUNOTHERAPY" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_10" STRING="MEK inhibition" FREQUENCY=1 START=1321 END=1335 LEMMA="MEK INHIBITION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_11" STRING="MEK inhibitors" FREQUENCY=2 START=218 END=232 LEMMA="MEK INHIBITOR" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_12" STRING="MEK inhibitors" FREQUENCY=2 START=218 END=232 LEMMA="MEK INHIBITOR" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_13" STRING="MEKi" FREQUENCY=1 START=234 END=238 LEMMA="MEK INHIBITORS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_14" STRING="Medical Oncology" FREQUENCY=1 START=541 END=557 LEMMA="MEDICAL ONCOLOGY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_15" STRING="Nivolumab" FREQUENCY=1 START=846 END=855 LEMMA="NIVOLUMAB" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_16" STRING="addition" FREQUENCY=1 START=1128 END=1136 LEMMA="ADDITION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_17" STRING="anti-CTLA-4 agent" FREQUENCY=1 START=162 END=179 LEMMA="ANTI-CTLA-4 AGENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_18" STRING="anti-PD-1 agent" FREQUENCY=1 START=612 END=627 LEMMA="ANTI-PD-1 AGENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_19" STRING="anti-PD-1 drug" FREQUENCY=1 START=249 END=263 LEMMA="ANTI-PD-1 DRUG" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_20" STRING="choice chemotherapy" FREQUENCY=1 START=825 END=844 LEMMA="CHOICE CHEMOTHERAPY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_21" STRING="clinical trial findings" FREQUENCY=1 START=1365 END=1388 LEMMA="CLINICAL TRIAL FINDING" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_22" STRING="congress" FREQUENCY=1 START=570 END=578 LEMMA="CONGRESS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_23" STRING="dynamic field" FREQUENCY=1 START=1549 END=1562 LEMMA="DYNAMIC FIELD" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_24" STRING="dynamic field of oncology" FREQUENCY=1 START=1549 END=1574 LEMMA="ONCOLOGY DYNAMIC FIELD" LEMMA_FREQUENCY=1 HEAD_TERM="dynamic field" HEAD_LEMMA="DYNAMIC FIELD"
TERM ID="NYU_TERM_25" STRING="immunotherapies" FREQUENCY=1 START=1051 END=1066 LEMMA="IMMUNOTHERAPY" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_26" STRING="immunotherapy" FREQUENCY=1 START=1149 END=1162 LEMMA="IMMUNOTHERAPY" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_27" STRING="investigator" FREQUENCY=1 START=810 END=822 LEMMA="INVESTIGATOR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_28" STRING="ipilimumab" FREQUENCY=2 START=181 END=191 LEMMA="IPILIMUMAB" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_29" STRING="ipilimumab" FREQUENCY=2 START=729 END=739 LEMMA="IPILIMUMAB" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_30" STRING="key highlights" FREQUENCY=1 START=499 END=513 LEMMA="KEY HIGHLIGHT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_31" STRING="melanoma" FREQUENCY=4 START=82 END=90 LEMMA="MELANOMA" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_32" STRING="melanoma" FREQUENCY=4 START=320 END=328 LEMMA="MELANOMA" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_33" STRING="melanoma" FREQUENCY=4 START=466 END=474 LEMMA="MELANOMA" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_34" STRING="melanoma" FREQUENCY=4 START=1436 END=1444 LEMMA="MELANOMA" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_35" STRING="metastatic melanoma" FREQUENCY=1 START=685 END=704 LEMMA="METASTATIC MELANOMA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_36" STRING="mg/kg" FREQUENCY=1 START=787 END=792 LEMMA="MG/KG" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_37" STRING="nivolumab" FREQUENCY=1 START=775 END=784 LEMMA="NIVOLUMAB" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_38" STRING="oncology" FREQUENCY=1 START=1566 END=1574 LEMMA="ONCOLOGY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_39" STRING="pembrolizumab" FREQUENCY=2 START=265 END=278 LEMMA="PEMBROLIZUMAB" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_40" STRING="pembrolizumab" FREQUENCY=2 START=1090 END=1103 LEMMA="PEMBROLIZUMAB" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_41" STRING="response rate" FREQUENCY=1 START=885 END=898 LEMMA="RESPONSE RATE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_42" STRING="targeted agents" FREQUENCY=1 START=1197 END=1212 LEMMA="TARGETED AGENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_43" STRING="treatment algorithms" FREQUENCY=1 START=1011 END=1031 LEMMA="TREATMENT ALGORITHM" LEMMA_FREQUENCY=1
